Tricida (TCDA) Tops Q2 EPS by 30c

Tricida (NASDAQ: TCDA) reported Q2 EPS of ($1.16), $0.30 better than the analyst estimate of ($1.46).

“While we won’t speculate what the FDA notification may entail, we are preparing for all eventualities to swiftly resolve any potential issues. However, we remain confident in the fundamentals of veverimer and its underlying value proposition,” said Gerrit Klaerner, Ph.D., Tricida’s Chief Executive Officer and President. “I am reassured by the feedback that we have received from our Specialty Account Managers from their initial interactions with community nephrologists that confirms the unmet need to treat metabolic acidosis.”

For earnings history and earnings-related data on Tricida (TCDA) click here.

You May Also Be Interested In

• CalPrivate Bank names Andra Frazier as chief credit officer
• NNN REIT adds two directors amid board succession planning
• Fabrinet (FN) Tops Q4 EPS by 29c, Beats on Revenue; Offers Guidance